Long-term follow-up of at least five years after recombinant human thyrotropin compared to levothyroxine withdrawal for thyroid remnant ablation with radioactive iodine

Thyroid

Volumn 22, Issue 3, 2012, Pages 332-333

  Rosario, Pedro Weslley ^a,b   Mineiro Filho, Augusto Flávio Campos ^a   Lacerda, Rafaela Xavier ^a   Calsolari, Maria Regina ^b  

^a Santa Casa de Belo Horizonte   (Brazil)

^b Endocrinology Service   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

IODINE 131; LEVOTHYROXINE; RECOMBINANT THYROTROPIN;

CANCER HORMONE THERAPY; CANCER RECURRENCE; CANCER SURGERY; DRUG WITHDRAWAL; FOLLOW UP; HUMAN; LETTER; PRIORITY JOURNAL; QUALITY OF LIFE; RADIOISOTOPE THERAPY; THYROID CARCINOMA; THYROIDECTOMY;

ADULT; FEMALE; FOLLOW-UP STUDIES; HUMANS; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; RADIOPHARMACEUTICALS; THYROID NEOPLASMS; THYROIDECTOMY; THYROTROPIN ALFA; THYROXINE;

EID: 84857807928     PISSN: 10507256     EISSN: 15579077     Source Type: Journal    
DOI: 10.1089/thy.2011.0242     Document Type: Letter

References (4)

1. Rosario PW, Borges MA, Purisch S 2008 Preparation with recombinant human thyroid-stimulating hormone for thyroid remnant ablation with 131I is associated with lowered radiotoxicity. J Nucl Med 49:1776-1782.
2. Rosario PW, Salles DS, Purisch S 2009 Area under the curve of TSH after levothyroxine withdrawal versus administration of recombinant human TSH (rhTSH): Possible implications for tumor growth. Arq Bras Endocrinol Metabol 53: 767-770.
3. Rosario PW, Malard Xavier AC, Calsolari MR 2010 Recombinant human TSH (rhTSH) in thyroid remnant ablation with 131-iodine in high risk patients. Thyroid 20: 1247-1252.
4. Rosario PW, Malard Xavier AC 2011 Recombinant human TSH (rhTSH) in thyroid remnant ablation with 1.1 GBq 131-iodine in low risk patients. Am J Clin Oncol [Epub ahead of print]; DOI: 10.1097/COC.0b013e318201a41a.